drugset / Trial / NCT06807606

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

NCT06807606

Phase 2 Recruiting 35 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control high-risk hematological malignancies in patients who need a second allogeneic stem cell transplantation.

Timeline

Start
2025-03-03
Primary completion
2027-11-30
Completion
2029-11-30

Drugs

EvaluationDrugModalityDoseRoute
Background Cyclophosphamide Other / unclassified Intravenous
Background Fludarabine Small molecule Intravenous
Background Mycophenolate Mofetil Small molecule Intravenous
Background Tacrolimus Small molecule Intravenous
Background Thiotepa Other / unclassified Intravenous